Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD 10: F 43.1) or personality disorder (ICD 10: F 60.-): clinical trial for genotypying of two metabolizing enzymes (CYP2D6 und CYP3A5*3). (Erhöhte Eliminationsraten von Quetiapin bei jugendlichen Patienten mit Schizophrenie (ICD 10: F 20.-), bipolar affektiver Störung (ICD 10: F 31.-) bzw. Störung der Impulskontrolle bei vorliegender PTBS (ICD 10: F 43.1) oder Persönlichkeitsstörung (ICD 10: F 60.-): Klinische Studie zur Genotypisierung zweier metabolisierender Enzyme (CYP2D6 und CYP3A5*3).)

X
Trial Profile

Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD 10: F 43.1) or personality disorder (ICD 10: F 60.-): clinical trial for genotypying of two metabolizing enzymes (CYP2D6 und CYP3A5*3). (Erhöhte Eliminationsraten von Quetiapin bei jugendlichen Patienten mit Schizophrenie (ICD 10: F 20.-), bipolar affektiver Störung (ICD 10: F 31.-) bzw. Störung der Impulskontrolle bei vorliegender PTBS (ICD 10: F 43.1) oder Persönlichkeitsstörung (ICD 10: F 60.-): Klinische Studie zur Genotypisierung zweier metabolisierender Enzyme (CYP2D6 und CYP3A5*3).)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Midazolam (Primary) ; Quetiapine (Primary)
  • Indications Bipolar disorders; Impulse control disorders; Personality disorders; Post-traumatic stress disorders; Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 14 Mar 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top